These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. HLA expression and tumor-infiltrating immune cells in uveal melanoma. de Waard-Siebinga I; Hilders CG; Hansen BE; van Delft JL; Jager MJ Graefes Arch Clin Exp Ophthalmol; 1996 Jan; 234(1):34-42. PubMed ID: 8750848 [TBL] [Abstract][Full Text] [Related]
44. Computer database for melanoma: a clinical management and research tool to ensure continuous quality assessment. Reintgen D; Cruse CW; Schroer K; Glass F; Saba H; Puleo C; King J; Berman C; Hannon L; Cox C Semin Surg Oncol; 1993; 9(3):208-14. PubMed ID: 8516605 [TBL] [Abstract][Full Text] [Related]
45. Stable and strong expression of basic fibroblast growth factor in naevus cell naevus contrasts with aberrant expression in melanoma. Ueda M; Funasaka Y; Ichihashi M; Mishima Y Br J Dermatol; 1994 Mar; 130(3):320-4. PubMed ID: 8148272 [TBL] [Abstract][Full Text] [Related]
46. The effect of misdiagnosis and delay in diagnosis on clinical outcome in melanomas of the foot. Bennett DR; Wasson D; MacArthur JD; McMillen MA J Am Coll Surg; 1994 Sep; 179(3):279-84. PubMed ID: 8069422 [TBL] [Abstract][Full Text] [Related]
47. The clinical experience with interleukin-2 in cancer therapy. Dillman RO Cancer Biother; 1994; 9(3):183-209. PubMed ID: 7820182 [TBL] [Abstract][Full Text] [Related]
48. Correlation between malignancy level of AKR lymphoma variants and sensitivity to hyperthermia. Leibovici J; Klorin G; Klein O; Michowitz M Cancer Biother; 1995; 10(1):53-60. PubMed ID: 7780488 [TBL] [Abstract][Full Text] [Related]
49. Binding of vitamin E in mammalian tumor cells in culture. Prasad KN; Gaudreau D; Brown J Proc Soc Exp Biol Med; 1981 Feb; 166(2):167-74. PubMed ID: 7208478 [No Abstract] [Full Text] [Related]
51. Measurement of the rate of death of dog tumour cells transplanted into athymic "nude" mice. Holmes JM J Comp Pathol; 1981 Oct; 91(4):511-9. PubMed ID: 6947997 [No Abstract] [Full Text] [Related]
52. Inhibition of tyrosinase activity by 4-tert-butylcatechol and other depigmenting agents. Usami Y; Landau AB; Fukuyama K; Gellin GA J Toxicol Environ Health; 1980 May; 6(3):559-67. PubMed ID: 6775084 [TBL] [Abstract][Full Text] [Related]
54. Working session report: in vivo-in vitro screening. Venditti JM Cancer Chemother Rep 3; 1972 May; 3(1):57-62. PubMed ID: 5049711 [No Abstract] [Full Text] [Related]
55. The incidence of malignant melanoma (0 to 15 years of age) arising in "large" congenital nevocellular nevi. Quaba AA; Wallace AF Plast Reconstr Surg; 1986 Aug; 78(2):174-81. PubMed ID: 3725963 [TBL] [Abstract][Full Text] [Related]
57. Differentiation antigens of melanoma and melanocytes. Houghton AN; Cordon-Cardo C; Eisinger M Int Rev Exp Pathol; 1986; 28():217-48. PubMed ID: 3516910 [No Abstract] [Full Text] [Related]
58. Effect of cyclophosphamide on the immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats. Harkonen S; Mischak R; Lopez H; Stoudemire J Cancer Drug Deliv; 1987; 4(3):151-7. PubMed ID: 3502453 [TBL] [Abstract][Full Text] [Related]
59. Steroids and neuroendocrine hormones detected by the immunoperoxidase technique from malignant melanomas and nevi of the choroid and conjunctiva. Di Tondo U; Balestrazzi E; Santeusanio G; Pintucci S; Spadea L Ophthalmologica; 1986; 192(1):34-8. PubMed ID: 3010209 [TBL] [Abstract][Full Text] [Related]
60. Lymphoscintigraphy as a guide to treatment in malignant melanoma. Woods JE; Freedman AM; Brown ML Ann Plast Surg; 1989 Feb; 22(2):150-5. PubMed ID: 2735710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]